Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Summary

This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have spread to the brain. Gadobutrol is a type of contrast agent that may increase DCE-MRI sensitivity for the detection of tumors or other diseases of the central nervous system. It is not yet known whether gadobutrol is more effective than standard of care contrast agents before DCE-MRI in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have spread to the brain.

Conditions

• Adult Anaplastic (Malignant) Meningioma
• Adult Anaplastic Astrocytoma
• Adult Anaplastic Ependymoma
• Adult Anaplastic Oligodendroglioma
• Adult Brain Stem Glioma
• Adult Choroid Plexus Neoplasm
• Adult Diffuse Astrocytoma
• Adult Ependymoblastoma
• Adult Ependymoma
• Adult Giant Cell Glioblastoma
• Adult Glioblastoma
• Adult Gliosarcoma
• Adult Grade II Meningioma
• Adult Medulloblastoma
• Adult Mixed Glioma
• Adult Oligodendroglioma
• Adult Papillary Meningioma
• Adult Pineal Gland Astrocytoma
• Adult Pineoblastoma
• Adult Primary Melanocytic Lesion of Meninges
• Adult Supratentorial Primitive Neuroectodermal Tumor
• Malignant Adult Intracranial Hemangiopericytoma
• Metastatic Malignant Neoplasm in the Brain
• Multiple Sclerosis
• Recurrent Adult Brain Neoplasm

Interventions

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo DCE-MRI

DRUG

Gadobenate Dimeglumine

Given IV

DRUG

Gadobutrol

Given IV

RADIATION

Gadopentetate Dimeglumine

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• University of Southern California

  lead OTHER

Principal Investigators

• Meng Law · University of Southern California

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-12-14

Primary Completion

2014-10-14

Completion

2015-10-14

Countries

• United States

Study Locations